Last reviewed · How we verify
CAB + RPV
CAB + RPV is a long-acting injectable combination of cabotegravir (an integrase inhibitor) and rilpivirine (a non-nucleoside reverse transcriptase inhibitor) that suppresses HIV replication by blocking two critical steps in the viral life cycle.
CAB + RPV is a long-acting injectable combination of cabotegravir (an integrase inhibitor) and rilpivirine (a non-nucleoside reverse transcriptase inhibitor) that suppresses HIV replication by blocking two critical steps in the viral life cycle. Used for HIV-1 infection in treatment-experienced adults as maintenance therapy, HIV-1 infection in treatment-naive adults as maintenance therapy.
At a glance
| Generic name | CAB + RPV |
|---|---|
| Sponsor | Allegheny Singer Research Institute (also known as Allegheny Health Network Research Institute) |
| Drug class | Long-acting injectable antiretroviral combination (integrase inhibitor + non-nucleoside reverse transcriptase inhibitor) |
| Target | HIV integrase and HIV reverse transcriptase |
| Modality | Small molecule |
| Therapeutic area | Infectious Disease / Virology |
| Phase | Phase 3 |
Mechanism of action
Cabotegravir inhibits HIV integrase, preventing the viral genome from integrating into host cell DNA. Rilpivirine inhibits reverse transcriptase, blocking the conversion of viral RNA to DNA. Together, this dual-mechanism approach provides potent antiretroviral activity with a high barrier to resistance. The long-acting injectable formulation allows for monthly or bimonthly dosing, improving adherence compared to daily oral therapy.
Approved indications
- HIV-1 infection in treatment-experienced adults as maintenance therapy
- HIV-1 infection in treatment-naive adults as maintenance therapy
Common side effects
- Injection site reactions (pain, erythema, induration)
- Headache
- Pyrexia
- Fatigue
- Nausea
- Diarrhea
Key clinical trials
- Study to Evaluate the Efficacy, Safety, and Tolerability of Long-acting Intramuscular Cabotegravir and Rilpivirine for Maintenance of Virologic Suppression Following Switch From an Integrase Inhibitor in HIV-1 Infected Therapy Naive Participants (PHASE3)
- Antiviral Long Acting Drugs Landing in People Living With HIV (NA)
- A Study to Evaluate the Efficacy, Safety, Participant Choice and Preference of an Oral Once-daily Regimen or a Long-acting Injectable Regimen Every Two Months for Treatment of Human Immunodeficiency Virus (HIV-1) in Adults Who Have Not Previously Taken Antiretroviral Therapy (PHASE3)
- A Study to Evaluate the Effectiveness of Long-acting (LA) Cabotegravir (CAB) + Rilpivirine (RPV) LA When Given to Participants With Detectable HIV-1 (PHASE3)
- HIV Outpatient Monitoring Evaluation Through Self-collection of Dried Blood Spots
- Implementation of Long-acting Cabotegravir + Rilpivirine Administration Out of "HIV Units". (NA)
- Combined Injectable Treatment for HIV and OUD (PHASE2)
- Study of B/F/TAF in Participants Switching From CAB + RPV to B/F/TAF for HIV-1 Infection (EMPOWER) (PHASE4)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape: